华厦眼科 reported revenue of ¥2.19B for the period ended 2026-06-30, +2.2% year on year. Net income was ¥0.30B, a 13.9% net margin on a 44.1% gross margin. The largest revenue line is 屈光项目 at 39% of the total. Free cash flow for the period was ¥0.13B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥2.19B | +2.2% |
| Gross profit | ¥0.96B | — |
| Operating income | ¥0.40B | — |
| Net income | ¥0.30B | +1.0% |
| Gross margin | 44.1% | Net margin 13.9% |
| Revenue Q/Q | -10.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 屈光项目 | ¥0.86B | 39.2% |
| 眼视光综合项目 | ¥0.53B | 24.4% |
| 白内障项目 | ¥0.41B | 18.6% |
| 眼后段项目 | ¥0.30B | 13.8% |
| 其他业务收入 | ¥0.09B | 4.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.22B | 55.9% |
| R&D | ¥0.03B | 1.4% |
| SG&A | ¥0.53B | 24.5% |
| Tax & other | ¥0.10B | 4.4% |
| Item | Amount |
|---|---|
| Total assets | ¥7.79B |
| Total liabilities | ¥2.19B |
| Shareholders' equity | ¥5.60B |
| Equity / assets | 71.9% |
| Operating cash flow | ¥0.18B |
| Capital expenditure | ¥0.05B |
| Free cash flow | ¥0.13B |
| Cash conversion (OCF / net income) | 158% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
铭利达 ・ 汉仪股份 ・ 英华特 ・ 瑞晨环保 ・ 汉朔科技 ・ 嘉曼服饰 ・ 新天地 ・ 快可电子 ・ 金道科技 ・ 珠城科技 ・ 科源制药 ・ 金禄电子
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies